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ABSTRACT 
INTRODUCTION: Socioeconomic inequalities in cancer survival are well documented 
but they differ for different cancers and over time. Reasons for these differences are 
poorly understood. 
PATIENTS AND METHODS: For England and Wales, we examined trends in socio-
economic survival inequalities for breast cancer in women and rectal cancer in men 
during the 32-year period 1973-2004.  We used a theoretical framework based on 
Victora’s ‘inverse equity’ law, under which survival inequalities could change with the 
advent of successive new treatments, of varying effectiveness, which are disseminated 
with different speed among patients of different socioeconomic groups.  We estimated 5-
year relative survival for patients of different deprivation quintiles and examined trends in 
survival inequalities in light of major treatment innovations. 
RESULTS: Inequalities in breast cancer survival (921,611 cases) narrowed steadily 
during the study (from -10% to -6%). In contrast, inequalities in rectal cancer survival 
(187,104 cases) widened overall (form -5% to -11%) with fluctuating periods of 
narrowing inequality.  
CONCLUSION: Trends in socioeconomic differences in tumour or patient factors are 
unlikely explanations of observed changes over time in survival inequalities. The 
sequential introduction into clinical practice of new treatments of progressively smaller 
incremental benefit may partly explain the reduction in inequality in breast cancer 
survival.  
 
Key words: Breast, Cancer, Colorectal, Deprivation, Inequality, Survival, Trends, 
Socioeconomic.  
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INTRODUCTION 
 
Wide socioeconomic inequalities in survival have been reported for many cancers.[1,2]  
Evidence on the causes of these inequalities remains limited, but they may at least partly 
reflect differences in clinical management (the ‘healthcare factors’ hypothesis).[1,2]  If 
this hypothesis were correct, socioeconomic inequalities should be largely determined 
by socio-economic differences in the quality of treatment received, with deprived patients 
more often managed sub-optimally.  Directly examining this hypothesis is difficult, 
however, because the treatment information routinely collected by cancer registries, at 
least historically, is usually in the form of binary (yes/no) information about the main 
treatment modalities (surgery, radiotherapy, chemotherapy) given within six months of 
diagnosis, with no information on the timeliness and technical excellence of surgery, or 
the timeliness, nature, dose and sequencing of radiotherapy or chemotherapy regimes. 
  
An alternative approach is to examine long-term trends in survival inequalities to identify 
whether the ‘advent’ of major new treatments was followed by narrowing or widening of 
inequalities in survival.  We use the term ‘advent’ to denote the timing of market 
authorisation of new drug therapies; or of the introduction into clinical practice of new 
surgical and radiotherapy techniques, also often associated with peer-reviewed 
publication of ‘key’ relevant studies.  This approach is inferior to direct examination of the 
impact of new treatments on survival using individual patient data, but it may provide 
insights into the interpretation of historical changes in survival inequalities during periods 
when population-based cancer treatment data were absent or rudimentary. 
 
The ‘inverse equity law’ is a conceptual framework, proposed by Victora and 
colleagues,[3] as an extension of Hart’s ‘inverse care law’,[4] within which the advent of 
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a single new treatment may generate healthcare inequalities that are later resolved.  
According to this framework, inequality in use of a specific healthcare intervention 
widens soon after its introduction but later narrows, until it ceases to exist (Figure 1).  
Evidence exists for time-lagged dissemination of new interventions among lower 
socioeconomic groups for cervical cancer screening,[5] measles, mumps and rubella 
(MMR) immunisation,[6] and primary care quality improvements for chronic diseases 
other than cancer.[7]  
 
Applying Victora’s framework to cancer care is challenging, as it typically involves 
combinations of different treatment modalities (e.g. surgery, chemotherapy or 
radiotherapy).  Step-wise but marginal improvements in survival following introduction of 
a new drug, for example, may be difficult to detect against underlying trends attributable 
to refinement and wider dissemination of older treatments, or to improvements in the 
organisation of services.  Testicular cancer provides a rare example of very rapid 
improvement in survival outcomes soon after the introduction of a single, new and highly 
effective treatment, platinum-based chemotherapy, in the 1970s.[8] Newer cancer 
treatments are now introduced into clinical practice frequently, so identifying the 
treatment(s) responsible for socio-economic inequalities in survival at any point in time 
may be difficult.  Moreover, socio-economic inequalities in access to newer treatments 
may be arising at the same time that inequalities in the use of more established 
treatments are being resolved (Figure 1).  For these reasons, the evolving causes of 
inequality in cancer survival, and the likely role of specific healthcare interventions at 
different times, may be difficult to establish with precision.  The relative effectiveness of 
new vs. existing treatments is also relevant. If newer treatments are much more effective 
than existing ones, inequalities in survival are likely to widen, whereas if newer 
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treatments are only marginally more effective, then inequalities in outcomes are likely to 
narrow. 
 
We examined changes in socioeconomic inequalities in survival for breast cancer in 
women and rectal cancer in men in England and Wales over the 32-year period 1973-
2004.  We chose these cancers because they are common, and because socioeconomic 
inequalities in survival became narrower during the 1980s and 1990s for breast cancer, 
but became wider for rectal cancer.[9,10]  We also examined whether any inflection in 
the underlying survival trends (and socio-economic inequalities) could be linked to the 
advent of new treatments considered to have been major advances in cancer 
management during this period. 
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Figure 1. When an effective new treatment (A) first becomes available, its use is initially 
higher among more affluent patients. Later, uptake increases among more deprived 
patients, eventually catching up with levels in affluent groups. Equal use of the treatment 
is reached after a lag period has elapsed. However the cycle may start again, for another, 
newer, treatment (B), giving rise to another inequality-equality lag cycle, and perpetuating 
socio-economic inequalities in healthcare. 
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METHODS 
 
Two cancer specialists with extensive experience in the management of cancers of the 
breast (MB) and rectum (MRT) summarised the most important developments in the 
clinical management of breast and rectal cancers since 1971, and provided insight into 
the timing of their introduction to cancer management in the UK.  This information was 
provided without knowledge of the findings of the study.   
 
Cancer registrations were available from the Office for National Statistics for residents of 
England and Wales diagnosed with breast or rectal cancer during the 36-year period 
1971-2006 and followed up to 31 December 2007.  Patients were assigned to one of five 
categories of socioeconomic deprivation (1 most affluent; 5 most deprived) using area-
based measures.  The Carstairs deprivation index score of the Census Enumeration 
District of residence was used for patients diagnosed during 1971-1995 (relating to the 
1981 and 1991 Censuses for patients diagnosed 1971-1985 and 1986-1995, 
respectively).[11]  The Index of Multiple Deprivation (IMD) 2004 score of the Lower 
Super-Output Area of residence was used for patients diagnosed during 1996-2006 
(2001 Census).[12]  Use of these different deprivation indices has been shown not to 
introduce bias in relation to relative survival deprivation estimates.[13,14] 
 
Relative survival up to five years after diagnosis was estimated for each calendar year of 
diagnosis 1971-2006 and each deprivation group, with a STATA algorithm,[8] 
(http://www.lshtm.ac.uk/ncdeu/cancersurvival/tools/index.htm) adapting methods 
developed by Esteve and colleagues.[15]  Relative survival estimates the cancer-related 
survival, adjusting for background mortality in the general population.  For England and 
Wales separately, the background mortality was provided by complete (single-year-of-
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age) life tables by sex, calendar year and deprivation category.  For 2006 and 2007, the 
2005 life tables were used because relevant mortality data were unavailable.  The cohort 
approach was used for 5-year relative survival for patients diagnosed during 1971-2002, 
since at least 5 years’ follow-up was available for all patients.  For patients diagnosed 
during 2003-2006, short-term predictions of survival were made with the period 
approach,[16] and with the hybrid approach for patients diagnosed in 2007.[17]  
Stratification by year of diagnosis (32 years) and deprivation (5 categories) produced 
160 strata, and even with these very common cancers, the precision of year-on-year 
survival estimates was reduced, so trends were smoothed with five-year moving 
averages.  
 
We estimated trends in relative survival at one year and five years after diagnosis, and 
at five years conditional upon one-year survival, for each deprivation group. For brevity, 
only the plots of five-year survival for the least and most deprived groups are presented 
in the article.  Absolute deprivation gaps in five-year survival were calculated as the 
simple differences between the fitted survival estimates for the most and the least 
deprived groups derived from a linear regression model.  These were displayed 
graphically and inspected for temporal change in survival inequalities. 
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RESULTS 
 
Data for 921,611 women with breast cancer and 187,104 men with rectal cancer 
diagnosed during the period 1971-2006 were included in the analyses.  
 
For women with breast cancer, five-year relative survival improved steadily from 55% to 
85% between 1973 and 2004.  Survival improved in each deprivation group, and the 
deprivation gap in survival has narrowed gradually over most of the 32-year period (from 
-10% to nearly -6%), except for two brief periods in the early 1980s and early 1990s, 
during which it was more stable (Figure 2).  
 
During the study period, adjuvant chemotherapy had been shown to be effective 
originally in 1976 and with an increasingly supportive evidence basis thereafter during 
the 1980’s.[18,19]  Similarly, endocrine therapy had been shown to be effective during 
the 1980’s,[18] with evidence also emerging from UK trials.[20,21]  The UK breast 
cancer screening programme was introduced gradually from 1988 to 1993.[22]   
 
Five-year relative survival for men with rectal cancer improved from 29% to 53% 
between 1973 and 2004 (Figure 3).  Survival increased in each deprivation group, but 
not at the same pace, and the survival deficit has widened from -5% to -11% since the 
1970s.  Two distinct ‘cycles’ can be seen.  The deprivation gap in survival narrowed 
slightly in the late 1970s but then widened even more by the mid-1980s; a second ‘cycle’ 
of this type occurred between the late 1980s and the early 1990s, and the deprivation 
gap has remained greater than -10% since the late 1990s.   
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Effective interventions for rectal cancer introduced during the study period included 
increasing use of flexible sigmoidoscopy since the 1970s; improvements in the quality of 
surgery because of specialisation since the early 1990s and thereafter (also resulting in 
decreasing post-operative mortality);[23,24,25] introduction of ‘Total Mesorectal 
Excision’, first described in 1986,[26] and further developed and disseminated 
throughout the 1990s;[27] more frequent use of pre-operative radiotherapy, with 
conclusive evidence of efficacy since 2000,[28] and more frequent use of adjuvant 
chemotherapy.[29,30]  Increasing use of liver resection surgery to manage metastatic 
disease in patients who present with operable liver involvement was apparent in late 
1990s and beyond.[31] 
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Figure 2. Trends in 5-year relative survival (%) from breast cancer in women in the most 
affluent and most deprived groups, and deprivation gap (%) in survival: 5-year moving 
average values, England and Wales, 1973-2004. Periods of emergence of evidence about the 
efficacy of new interventions are denoted on the graph. 
 
 
 
 
Figure 3. Trends in 5-year relative survival (%) from rectal cancer in men in the most 
affluent and most deprived groups, and the deprivation gap (%) in survival: 5-year moving 
average values, England and Wales, 1973-2004. Periods of emergence of evidence about the 
efficacy of new interventions are denoted on the graph. Increasing use of flexible sigmoidoscopy 
occurred throughout the study period, and is not denoted on the graph. 
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DISCUSSION 
 
We report contrasting long-term trends in socio-economic inequalities in survival for two 
common cancers.  For breast cancer in women, the deprivation gap in five-year survival 
narrowed slowly steadily from the early 1970s to the mid-2000s, whereas for rectal 
cancer in men, survival inequalities widened substantially over the 32-year period, but 
followed a more complex pattern with two periods of narrowing inequality.  The findings 
extend the observation period of previously reported trends in overall survival,[9,10] and 
suggest that for breast cancer, the narrowing of the deprivation gap in survival continues 
a trend from the early 1970s. 
 
Trends in socio-economic inequality in survival could relate to socio-economic 
differences in tumour factors (such as morphology and stage); patient factors (such as 
co-morbidity); healthcare factors (such as differential diffusion over time of effective new 
interventions), and non-cancer mortality.[1,2,32]   For such factors to explain changes 
over time in survival inequalities, they should account for at least part of the deprivation 
gap at the start of the observation period, and also be considered capable of accounting 
for subsequent change in the deprivation gap over time. 
 
Changes in the socioeconomic distribution of tumour morphology and biology (reflecting 
prior socioeconomic differences in exposure to risk factors associated with tumour types 
of different prognosis) are an unlikely explanation of the findings.  Evidence for the role 
of tumour factor differences as determinants of socioeconomic inequalities in survival is 
inconsistent.[1]  However, even if socioeconomic differences in risk factor exposure and 
tumour biology could explain survival inequalities cross-sectionally (i.e. at one point in 
time) for them to explain the continually narrowing survival gaps in breast cancer survival 
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during 1974-2006, they should have occurred continually during a period prior and 
during the examined study period.  We know of no evidence detailing such 
‘convergence’ or ‘divergence’ in socioeconomic differences in risk factor exposure or 
tumour type for either breast or rectal cancer.  Moreover, in relation to rectal cancer, 
socioeconomic differences in exposure to risk factors associated with more aggressive 
(poorer prognosis) tumour types ought not only to have been substantial initially, but 
should have also changed ‘direction’ twice during a period prior and during the study.  
Therefore, although we acknowledge that socioeconomic differences in tumour biology 
could account for a proportion of the observed differences in survival inequalities, we 
believe they are unlikely to represent a substantial cause of the observed substantial 
changes over time in survival inequalities in major part.   
 
Differential changes in the co-morbidity burden of cancer patients of different 
socioeconomic groups are also an unlikely explanation. Co-morbidity affects clinical 
decisions about treatment suitability; some research also postulates that it could lower 
host resistance to cancer.[33]  No data were available on co-morbidity in the cancer 
patients we studied, but there is evidence of either stable or widening inequalities in 
general fitness and co-morbidity in both sexes during the study period.[34,35,36] 
Although widening inequalities in co-morbidity could perhaps have contributed to 
widening inequalities in rectal cancer survival, it would be hard for this to explain 
narrowing inequalities in breast cancer survival, as co-morbidities constraining treatment 
(such as obstructive lung disease and coronary artery disease ) are the same for both 
cancers. Further, the direct effects of lethal co-morbidity are taken into account by the 
use of relative survival, which compensates for background mortality from other causes 
of death. 
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Changes over time in the socioeconomic distribution of mortality from unrelated causes, 
could in principle artificially ‘inflate’ or ‘decrease’ cancer survival.[32] However, this could 
not have biased the findings in relation to changes over time in survival inequality, 
because deprivation group-specific life tables were used. 
 
Trends in the socioeconomic distribution of stage could in principle be relevant. Given 
the time period of our study (starting in 1973) no population-based data were available 
on tumour stage.  Changes in mean stage at presentation are likely to have occurred 
during the study period, both because of secular improvements in patient and clinician 
awareness of early signs and symptoms of symptomatic disease, and because of 
organised screening activity. However, although differential improvement in stage at 
presentation in favour of more deprived patients could have been in part responsible for 
narrowing inequalities for breast cancer, it is difficult to reconcile this hypothesis with the 
observed increasing survival inequality observed for rectal cancer, which would have 
required inverse changes in the socioeconomic distribution of stage.  
 
The introduction of breast cancer screening during the study period has contributed to 
distinct improvement in relative survival.[37]  It is however unlikely that the introduction 
of breast screening could have contributed to narrowing survival inequalities, as 
screening uptake has been slightly higher among more affluent patients,[38,39] and 
therefore the net effect of such uptake differences could not have contributed the 
observed narrowing of survival inequalities.  
 
Having considered the potential role of changes over time in socioeconomic differences 
in respect of tumour and patient factors, and in competing mortality, we would wish to 
draw attention to the potential role of socioeconomic differences in the speed of 
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dissemination of newer treatments among patients of different deprivation groups during 
the study period.  Given the study period, we were not able to take into account in the 
analysis any information on the actual treatment provided to patients.  For more recent 
periods, and prospectively, it is hoped that use of linked datasets (e.g. of cancer 
registration with Hospital Episodes Statistics data) could help more accurately depict 
treatment patterns in the future (including information on the timeliness, nature and 
‘dose’ of treatments).[40] A key consideration is that following Victora’s hypothesis 
survival inequalities can be considered to be the final product of successive inequality 
phases in relation to treatments introduced in temporal sequence. Therefore, whether 
inequalities get narrower or wider is determined by whether successive innovations in 
management are more or less effective compared with previous and subsequent 
treatment innovations. 
 
Adjuvant chemotherapy, endocrine therapy (tamoxifen) and breast cancer screening 
were all introduced during the study period.   Most (i.e. about two thirds) of the observed 
reduction in breast cancer mortality in England and Wales between 1971 and 1997 is 
attributable to wider availability and use of chemotherapy and endocrine therapy, as 
opposed to earlier diagnosis because of screening.[37]  Concordant findings have been 
observed in the USA (1975-2000),[41] and Norway,[42] and also in Australia (1981-
1994) where substantial improvement in survival had been achieved before screening 
programmes were introduced.[43]  Therefore, the most effective (in terms of effect size) 
treatments for breast cancer during the study period appear to have been those 
relatively ‘old’ (but comparatively more effective) treatments gradually introduced in 
clinical practice during the 1970s and 1980s.  Both adjuvant chemotherapy and 
endocrine therapy are associated with up to 30% reduction in mortality, an effect size 
substantially larger to that derived by screening (15%).[44]  If a newer treatment is less 
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effective than an older one, survival inequality may narrow over time, because the lapse 
of a ‘lag’ period eventually enables equal use of the older and more effective treatment. 
The degree of ‘inequality resolution’ resulting from this change exceeds the ‘inequality 
generation’ resulting by the introduction of the newer (but less effective) treatment. 
Whilst a degree of inequality may prevail for relatively new interventions (such as breast 
cancer screening),[38,39] if their effect size is smaller than that of other, ‘older’ 
interventions, the net effect will be progressive narrowing of inequality – as observed in 
our study. Reduction of geographical inequalities in breast cancer survival between 
different regions against the background of improving overall population survival, were 
described in Denmark, reminiscent of our own findings,[45] which also concord with 
Australian research.[46]  Evidence from The Netherlands confirms substantial changes 
in clinical management during the study period.[47] 
 
Regarding rectal cancer, it has been postulated previously that widening survival 
inequalities for rectal cancer between 1986 and 1999 may have been caused by a 
combination of a differential socioeconomic trends in earlier diagnosis and clinical 
management.[48]  Rectal cancer provides a good example of the multi-modality of 
cancer management, with several tests and treatments being of great relevance to 
clinical management – most of which have been introduced and disseminated into 
clinical practical gradually during the study period.  Unlike breast cancer, it would appear 
that the succession of innovative treatments was ‘from less to more efficacious’, 
resulting in widening inequality.  However, the relatively large number of innovations in 
rectal cancer management during the study period makes the detection of their direct 
impact on population survival (in the absence of direct empirical prospective evidence on 
treatment use) challenging.  
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We have used five-year relative survival. Trends in survival inequality can also be 
compared for any other time period, e.g. one-year, three-year and five-year conditional 
upon one-year survival. We have indeed calculated such survival estimates, but on 
inspection, it was apparent there was no added value in presenting such analyses.  We 
opted to focus on inequalities in survival (as opposed in hazard of death) as survival is 
the most commonly used metric of population-based outcomes in cancer care, and so 
that our findings can be understood and interpreted more immediately by researchers, 
members of the public, and policy makers.[49]  Although in principle the choice of 
absolute or relative measures of inequality could give different interpretations,[50,51] in 
our own study examining relative differences in survival identifies similar change 
patterns over time.  There is no universal acceptance of consistently using either 
absolute or relative inequality measures, reason for which presenting actual 
(socioeconomic group specific) rates, as opposed to only presenting summary inequality 
measures such as rate differences or ratios is recommended,[50,51] and this is why we 
present actual rates as well as summary measures in our study. 
 
We have examined and report opposing (narrowing-widening) inequality trends during a 
32-year period for two common cancers and explored the potential role of different 
explanatory factors, and healthcare factors in particular.  Although the analysis relates to 
historical data, our findings could hold valuable lessons for policy makers of the present 
day.  Ongoing investment in prospective national audit datasets and registries could help 
to track diffusion of effective innovation in cancer treatment more effectively than it has 
been possible in the past, and help detect potential variation in use among different 
population subgroups.  Such policy initiatives that could enable the ‘early detection’ of 
inequality in process measures such as treatment use, help ‘reduce’ the length of 
‘natural’ treatment inequality lags resulting from the introduction of new treatments, and 
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accelerate the reduction of historical or prevent the generation of future inequalities in 
outcomes. Further studies including prospective data collection of treatment details 
could help amplify the empirical basis supporting the interpretation framework about 
social inequalities in survival that we propose in this paper.  
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Figure legends 
 
Figure 1. 
Figure 1. When an effective new treatment (A) first becomes available, its use is initially 
higher among more affluent patients. Later, uptake increases among more deprived 
patients, eventually catching up with levels in affluent groups. Equal use of the treatment 
is reached after a lag period has elapsed. However the cycle may start again, for another, 
newer, treatment (B), giving rise to another inequality-equality lag cycle, and perpetuating 
socio-economic inequalities in healthcare. 
 
Figure 2. 
Figure 2. Trends in 5-year relative survival (%) from breast cancer in women in the most 
affluent and most deprived groups, and deprivation gap (%) in survival: 5-year moving 
average values, England and Wales, 1973-2004. Periods of emergence of evidence about the 
efficacy of new interventions are denoted on the graph. 
 
Figure 3.   
Figure 3. Trends in 5-year relative survival (%) from rectal cancer in men in the most 
affluent and most deprived groups, and the deprivation gap (%) in survival: 5-year moving 
average values, England and Wales, 1973-2004. Periods of emergence of evidence about the 
efficacy of new interventions are denoted on the graph. Increasing use of flexible sigmoidoscopy 
occurred throughout the study period, and is not denoted on the graph. 
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